Does biomarker information impact breast cancer patients’ preferences and physician recommendation for adjuvant chemotherapy?
Open Access
- 23 June 2017
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 165 (3) , 545-553
Abstract
This study aimed to examine how biomarker information would impact patients’ preferences and physicians’ recommendations for adjuvant breast cancer therapy.Keywords
Funding Information
- National Cancer Institute (CA21115, CA180820, CA180821, CA077651, CA49883, CA13650, CA180794, CA180795, CA180816, CA180790, CA180867, CA180791, CA23318, CA031946, CA025224, CA66636)
- Susan G. Komen for the Cure (Promise Award)
This publication has 12 references indexed in Scilit:
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2016
- A New Initiative on Precision MedicineNew England Journal of Medicine, 2015
- Attitudes toward molecular testing for personalized cancer therapyCancer, 2014
- Experiences and attitudes toward risk of recurrence testing in women with breast cancer: a systematic reviewBreast Cancer Research and Treatment, 2014
- Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 TrialClinical Cancer Research, 2013
- Interest and attitudes of patients, cancer physicians, medical students and cancer researchers towards a spectrum of genetic tests relevant to breast cancer patientsThe Breast, 2013
- Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment SelectionJournal of Clinical Oncology, 2010
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100Journal of Clinical Oncology, 2008
- When genomic and standard test results diverge: implications for breast cancer patients’ preference for chemotherapyBreast Cancer Research and Treatment, 2008
- Threats to Applicability of Randomised Trials: Exclusions and Selective ParticipationJournal of Health Services Research & Policy, 1999